

## Management of antibody-drug conjugate (ADC) related ocular adverse events

**30 September 2025**

*WEBINAR*

**Time: 18:00 - 20:00 CEST**

ESASO Scientific Director: Mario Romano

Course Scientific Coordinator: Martina Angi

**Moderator: Martina Angi**

<b>Welcome and Introduction</b>	Moderator: Martina Angi (Italy)	<b>18:00-18:05</b> <b>5 Min.</b>
<b>ADCs: what are they and what do they do to the eye?</b>		<b>18:05-18:25</b>
Overview of ADCs used in oncology and their ocular adverse events	Ramin Khoramnia (Germany)	<b>20 Min.</b>
<b>Multidisciplinary approach in the management of ADC-related ocular adverse events</b>		<b>18:25-18:45</b>
Patients education and preventing strategies, referral pathways in case of symptoms, use of common terminology to grade toxicity, shared decision-making on treatment adjustment	Sajjad Ahmad (UK)	<b>20 Min.</b>
<b>Mirvetuximab Soravtansine (MIRV): a first-in-class ADC for platinum-resistant ovarian cancer</b>		<b>18:45-19:05</b>
Brief introduction on ovarian cancer, speaking about the unmet need in platinum resistant ovarian cancer and presenting the most important efficacy and safety data with MIRV	Elena Giudice (Italy)	<b>20 Min.</b>
<b>MIRV-related ocular adverse events and how to manage them</b>		<b>19:05-19:25</b>
Data on ocular safety profile of MIRV, emphasizing the differences to other ADCs, providing indications on the correct management of its ophthalmic side effects	Amadeu Carceller (Spain)	<b>20 Min.</b>

## eLOS ONLINE COURSE

<b>Real-life experience with MIRV: case 1</b> Patient case presentation and further considerations	Maximilian Groeben (Germany)	19:25-19:35  10 Min.
<b>Real-life experience with MIRV: case 2</b> Patient case presentation and further considerations	Gerald Schmidinger (Austria)	19:35-19:45  10 Min.
<b>Real-life experience with MIRV: case 3</b> Patient case presentation and further considerations	Maximilian Groeben (Germany)	19:45-19:55  10 Min.
<b>Discussion / Q &amp; A</b>	Moderator + All speakers	19:55-20:05 10 Min.
<b>Take home message and closing remarks</b>	Moderator: Martina Angi (Italy)	20:05-20:10 5 Min.

An application will be made to EACCME® for CME accreditation of this event.

Associated to



You can support the non-profit foundation even without donating.

Help us become more visible: follow our social media, share your experience, and tag us in photos/videos.

ESASO Foundation

Villa Saroli, Via Stefano Franscini 9

PO BOX 1170

6901 Lugano, Switzerland

Tel. +41 (0)91 921 11 54

Email [info.esaso.org](mailto:info.esaso.org)

Web [www.esaso.org](http://www.esaso.org)